The global Psoriasis Treatment industry was valued at USD 35.0 Bn in 2024 and is projected to surpass USD 87.6 Bn by the end of 2035, expanding at a CAGR of 9.5% from 2025 to 2035. Growth is driven by the rising prevalence of psoriasis, increasing adoption of biologic therapies, advancements in targeted treatments, and growing awareness of dermatological health.

Dive Deeper into Data: Get Your In-Depth Sample Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17960

The global psoriasis treatment market is witnessing steadiness, driven primarily by the increase in prevalence of psoriasis, rising awareness and advancements in biologic and targeted therapies. More number of patients are being diagnosed with psoriasis due to the overall increase in healthcare access and improved awareness, which increases the demand for effective treatment that offers long-term control of symptoms.

Key Findings of the Market Report

• Biologics dominate the therapy type, accounting for ~49.6% of the market share in 2026. Within this, Interleukin (IL) inhibitors (e.g., Skyrizi, Taltz, Cosentyx) are the fastest-growing sub-segment, surpassing older TNF-alpha inhibitors in new prescription volume.
• TNF-alpha Inhibitors still hold a significant revenue share (~41%), but face increasing price erosion due to the massive influx of biosimilars.
• Plaque Psoriasis is the leading indication, representing 80%–90% of cases and the majority of treatment revenue.
• Parenteral (Injectable) Administration leads the route of administration segment with a ~57.6% share, though Oral Small Molecules are growing the fastest (~11.5% CAGR) as patients seek "needle-free" alternatives.
• North America remains the dominant region (holding ~39.4%–44.7% share), while Asia-Pacific is the fastest-growing market due to rapid drug approvals in China and a rising geriatric population in Japan.

Global Psoriasis Treatment: Growth Drivers

• The TYK2 and Oral Peptide Revolution: 2026 marks the widespread adoption of Sotyktu (deucravacitinib) and emerging oral peptides (like icotrokinra). These provide a "middle ground" for patients who are dissatisfied with topicals but hesitant to start injectable biologics.
• Biosimilar Price Erosion vs. Volume Uptake: The "patent cliff" for major biologics is making high-efficacy treatments affordable for a larger global population, driving volume growth in previously underserved markets like Latin America and SE Asia.
• AI and Precision Dermatology: Diagnostic platforms (e.g., Mindera Health) are being used to predict a patient's response to specific biologics before treatment begins, reducing the "trial-and-error" period and improving long-term adherence.
• Increased Prevalence and Diagnosis: Higher awareness and improved diagnostic criteria are identifying more "moderate" patients who were previously only treated with OTC topicals, shifting them into the high-value systemic treatment category.

Global Psoriasis Treatment: Regional Landscape

• North America: The value leader, driven by high R&D spending and early adoption of premium IL-23 inhibitors.
• Europe: A mature market with high biosimilar penetration. Regulatory focus is on cost-containment, favoring the use of biosimilar adalimumab as a first-line systemic therapy.
• Asia-Pacific: The growth engine. China has significantly shortened its innovative-drug review time (from 2 years to 6 months), leading to a surge in novel biologic launches.

Global Psoriasis Treatment: Key Players

The market is highly competitive, with "Big Pharma" giants aggressively defending their franchises against a rising tide of biosimilars and oral innovators.

• AbbVie Inc. (Market leader with Skyrizi and Humira)
• Johnson & Johnson (Dominant with Tremfya and Stelara)
• Novartis AG (Leader in IL-17 therapy with Cosentyx)
• Eli Lilly and Company (Strong presence with Taltz and Olumiant)
• Amgen Inc. (Key player with Enbrel and Otezla)
• Bristol-Myers Squibb (Pioneer in TYK2 inhibitors with Sotyktu)
• UCB S.A. (Rising competitor with Bimzelx)
• Pfizer Inc.
• Leo Pharma A/S (Leader in topical and specialized dermatology)
• Sun Pharmaceutical Industries Ltd.

Recent Developments (2025–2026)

• February 2026: Biocon Biologics signed a landmark agreement with Janssen (J&J) to commercialize a biosimilar version of Stelara (ustekinumab), signaling the start of a major pricing shift in the IL-12/23 category.
• January 2026: Takeda/Nimbus Therapeutics released promising Phase III data for Zasocitinib, a TYK2 inhibitor showing superior skin clearance rates compared to current oral standards.
• Late 2025: The FDA granted expanded pediatric approval for several IL-23 inhibitors, opening up a new high-growth demographic for long-term biologic maintenance.

Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=17960&ltype=S

Global Psoriasis Treatment: Segmentation

By Drug Class

• Interleukin Inhibitors (Fastest Growing)
• TNF-alpha Inhibitors (Revenue Leader; faces biosimilar pressure)
• PDE4 Inhibitors (e.g., Otezla)
• TYK2 Inhibitors (High Growth Oral)
• Vitamin D Analogs & Corticosteroids (Topical Standards)

By Route of Administration

• Parenteral (Injectable/IV) — (Largest Share; ~57%)
• Oral — (Fastest Growth; ~11.5% CAGR)
• Topical

By Distribution Channel

• Hospital Pharmacies (Largest Share; ~42%)
• Retail Pharmacies (High Growth for oral/topical)
• Online Pharmacies

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com     
Email: sales@transparencymarketresearch.com